Home » Stocks » Plus Therapeutics

Plus Therapeutics, Inc. (PSTV)

Stock Price: $2.78 USD -0.21 (-7.16%)
Updated Aug 11, 2020 10:45 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 11.41M
Revenue (ttm) 6.38M
Net Income (ttm) -8.82M
Shares Out 4.11M
EPS (ttm) -30.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $2.78
Previous Close $2.99
Change ($) -0.21
Change (%) -7.16%
Day's Open 2.90
Day's Range 2.70 - 2.98
Day's Volume 128,632
52-Week Range 0.93 - 22.89

More Stats

Market Cap 11.41M
Enterprise Value 7.29M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 4.11M
Float 3.76M
EPS (basic) -6.5
EPS (diluted) -30.62
FCF / Share -1.09
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 145,625
Short Ratio 1.24
Short % of Float 6.37%
Beta 0.55
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1.79
PB Ratio 141.24
Revenue 6.38M
Operating Income -4.05M
Net Income -8.82M
Free Cash Flow -4.21M
Net Cash 4.12M
Net Cash / Share 1.00
Gross Margin 25.60%
Operating Margin -63.51%
Profit Margin -149.80%
FCF Margin -66.00%
ROA -10.78%
ROE -96.70%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$4.75*
Low
4.75
Current: $2.78
High
4.75
Target: 4.75
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue7.002.986.4111.3811.667.6012.2014.5010.0010.63
Revenue Growth134.6%-53.47%-43.66%-2.39%53.45%-37.7%-15.9%45.07%-5.94%-
Gross Profit7.002.985.099.218.474.668.7810.506.166.72
Operating Income-3.66-8.76-19.46-19.16-22.95-32.81-33.35-28.29-33.03-26.58
Net Income-10.89-12.63-22.69-22.05-18.74-37.37-26.18-32.28-32.45-27.49
Shares Outstanding1.380.170.060.030.020.010.010.010.010.01
Earnings Per Share-8.27-86.98-411.50-640.00-1,035.00-3,598.20-2,923.54-4,122.94-4,572.71-4,497.75
Operating Cash Flow-5.91-11.98-18.13-19.53-20.47-30.33-34.56-32.19-35.32-23.57
Capital Expenditures-0.07-0.13-0.180.06-0.60-0.694.48-1.20-0.56-0.61
Free Cash Flow-5.97-12.11-18.31-19.47-21.07-31.02-30.08-33.40-35.88-24.18
Cash & Equivalents17.595.3010.2312.9114.6914.9715.8626.0737.2753.02
Total Debt11.8514.2013.6217.6416.6825.4026.2922.6924.4519.71
Net Cash / Debt5.74-8.90-3.40-4.73-1.99-10.43-10.443.3812.8233.31
Assets23.2323.9931.6234.6137.7038.7242.0643.2551.5366.35
Liabilities22.0718.7718.6223.6225.4944.4238.9336.8041.5943.47
Book Value1.165.2313.0010.9912.21-5.703.136.469.9522.87
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Plus Therapeutics, Inc.
Country United States
Employees 12
CEO Marc H. Hedrick

Stock Information

Ticker Symbol PSTV
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PSTV

Description

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. Its lead product candidate is DocePLUS, a protein-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. The company is also involved in developing DoxoPLUS, a generic PEGylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and Kaposi's sarcoma. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.